Disability Burden In Patients With Tenosynovial Giant Cell Tumors In The United States From Employer Perspective.

Feng Lin,Raluca Ionescu-Ittu,Irina Pivneva,Willy Wynant,Sherry Shi,Azadeh Shohudi Mojdehi,Eric Q. Wu,Jackie Kwong,John A. Abraham
DOI: https://doi.org/10.1200/JCO.2018.36.30_suppl.92
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:92Background: Tenosynovial giant cell tumor (TGCT) is a rare locally aggressive tumor causing pain, swelling, joint destruction, and limited mobility. This study assessed the disability burden and the associated costs in TGCT patients from an employer’s perspective. Methods: A retrospective analysis was performed using medical and disability claims from the OptumHealth database. Incident patients 18-64 years old with a diagnosis of TGCT (as identified by ICD-9: 727.02, 719.2x; ICD-10: D48.1, D21.x, M12.2) were matched 1:10 to controls without TGCT based on age, gender, index year, and follow-up duration. Patients without earning and disability data were excluded. Days of work loss due to disability claims and absenteeism associated with medical visits were compared using Poisson regression models. Costs were compared using generalized linear models. Results: A total of 1,395 eligible TGCT patients were matched with 13,950 controls without TGCT. Despite similar demographics (36% female, mean age 45-47) and...
What problem does this paper attempt to address?